For many years, there has only been one oral GLP-1 available: Rybelsus
The review further distinguishes between established outcome benefits (CVD, CKD, and OSA) and conditions still under investigation (neurodegeneration, arthritis, and some liver endpoints)
Ozempic is a specific brand of GLP-1 receptor agonist used to manage type 2 diabetes and obesity
These findings also confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health." A new European consortium known as Sophia (Stratification of Obese Phenotypes to Optimize Future Obesity Therapy), led by scientists at University College Dublin, is now attempting to investigate this in more detail
PMID: 40609566 | doi:10.1016/S2213-8587(25)00092-0 Sinha B et al
Ozempic-type drugs mimic GLP-1, thereby tricking our body into thinking were eating all the time